Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Apr 21;9(1):241-5.
doi: 10.1159/000445939. eCollection 2016 Jan-Apr.

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma

Priscilla Denise Zepeda-Lopez  1 , Julio Cesar Salas-Alanis  2 , Sonia Toussaint-Caire  1 , Daniela Gutierrez-Mendoza  1 , Elisa Vega-Memije  1 , Saúl Lino Silva  3 , Oscar Raul Fajardo-Ramírez  2 , Gregorio Alcazar  4 , María Guadalupe Moreno-Treviño  2 , Hugo Alberto Barrera Saldaña  4
Affiliations
Free PMC article
Case Reports

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma

Priscilla Denise Zepeda-Lopez et al. Case Rep Oncol. .
Free PMC article

Abstract

Background: B-Raf is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. It has been shown that 50% of melanomas harbor activating BRAF mutations, with over 90% being the V600E mutation.

Objective: The goal of this research was to determine the prevalence of the BRAF V600E mutation in patients from Central Mexico diagnosed with primary melanoma.

Methods: Skin biopsies from 47 patients with melanoma were obtained from the dermatology department of the Hospital General 'Dr. Manuel Gea González' in Mexico City. For BRAF mutation determination, after DNA isolation, the gene region where the mutation occurs was amplified by PCR. Subsequently, the presence or absence of the V600E mutation was detected by Sanger sequencing performed at the private molecular diagnostic laboratory Vitagénesis in Monterrey, Mexico.

Results: Of the 47 patients sampled, 6.4% harbored the V600E mutation. No statistical significance was found between mutations and the type of tumor.

Keywords: BRAF; Melanoma; Mexican patients; V600E mutation.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD. Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol. 2011;12:913–922. - PubMed
    1. Heideman DA, Lurkin I, Doeleman M, Smit EF, Verheul HM, Meijer GA, Snijders PJ, Thunnissen E, Zwarthoff EC. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn. 2012;14:247–255. - PubMed
    1. Miller AJ, Mihm MC. Melanoma. N Engl J Med. 2006;355:51–65. - PubMed
    1. Thiam A, Zhao Z, Quinn C, Barber B. Years of life lost due to metastatic melanoma in 12 countries. J Med Econ. 2016;19:259–264. - PubMed
    1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–2516. - PMC - PubMed

Publication types